Wednesday, March 08, 2017 4:16:53 PM
Item 1.01 Entry into a Material Definitive Agreement
On January 31, 2017 HemCare Health Services Inc. (herein “The Company”) reached a settlement agreement to have 71,140,000 shares of its common stock returned for cancellation & rescission. The agreement also cancelled over $30,000 in The Company’s debt and interest related to an alleged Convertible Promissory Note signed by The Company's previous Chief Executive Officer. The forgiveness and cancellation of this note removes all convertible debt and protects the shareholders from increased dilution by now having removed all forms of convertible instruments currently outstanding. Under the terms of the Agreement The Company will stop its legal action and refrain from taking other such actions that may harm these shareholders and entities.
The settlement agreement was with 7 individuals and companies who were in possession of The Company’s common shares. These individuals and entities received these shares from the nominees of Ultroid Marketing Development Corp following its May 19, 2015 agreement to licensed perpetual rights to use Ultroid Marketing Development Corp’s products and the trade name “Ultroid System as described in The Company’s May 22, 2015 8K filed with the Securities & Exchange Commission.
The Company still believes there to be more than 28 million common shares outstanding that in management's opinion have been transferred and or acquired without proper consideration and under questionable circumstances relating to this transaction with Ultroid and its nominees. The Company has placed a “Stop Transfer” with its Transfer Agent and will continue to pursue all remedies for the legal order to cancel these shares and to recover costs and damages in doing so.
Also on January 31, 2017 The Company reached an agreement with its 9% Secured Promissory Note holder to retire $250,000 of outstanding principal & interest by way of the issuance of 12,500,000 common shares of the Company. As part of the agreement the note maturity date was extended to January 26, 2018 for the approximately $50,000 balance.
While management was successful in restructuring its debt and eliminating all convertible instruments there can be no assurance of its ability to meet future obligations or in its ability to obtain a court order and or costs and damages in recovering the shares discussed herein.
Recent DLTI News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 04:53:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 05:09:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2023 08:25:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 08:21:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 08:20:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 08:19:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM